Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges
The DOI matches its Crossref record; 176 of the 177 references it cites were found in a registry or an index.
Abstract
In vivo gene replacement for the treatment of inherited disease is one of the most compelling concepts in modern medicine. Adeno-associated virus (AAV) vectors have been extensively used for this purpose and have shown therapeutic efficacy in a range of animal models. Successful translation to the clinic was initially slow, but long-term expression of donated genes at therapeutic levels has now been achieved in patients with inherited retinal disorders and haemophilia B. Recent exciting results have raised hopes for the treatment of many other diseases. As we discuss here, the prospects and challenges for AAV gene therapy are to a large extent dependent on the target tissue and the specific disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This immune cascade model might explain why re-administration in patients could become difficult, and why the administration of rAAVs in patients with high neutralizing antibodies (nAbs) are generally not included in clinical trials [327].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [327]
Citations
Cites
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“The disease is currently treated by intravenous infusion of clotting factor concentrate”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Research works printed but not linked: 3
- Basner-Tschakarjan, E. et al. Dose-dependent activation of capsid-specific T cells after AAV serotype 8 vector administration in a clinical study for hemophilia. Mol. Ther. (in the press).
- Mingozzi, F. et al. Modulation of T cell response to the AAV capsid in subjects undergoing intramuscular gene transfer for lipoprotein lipase deficiency. Hum. Gene Ther. 19, 1090 (2008).
- Muzyczka, N. & Berns, K. I. in Parvoviridae: The Viruses and their Replication (eds Knipe, D. M. & Howley, P. M.) 2437–2477 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
Cited by
Items 401–500 of 892
Adeno-Associated Virus as an Effective Malaria Booster Vaccine Following Adenovirus Priming
Yusuf, Y., Yoshii, T., Iyori, M., Yoshida, K., Mizukami, H., Fukumoto, S., Yamamoto, D. S., Alam, A., Emran, T. B., Amelia, F., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00730 · Cited by 33
“Although both adenovirus and AAV have been shown to be safe in human trials (10, 48), a potential area of concern in their application as vaccine vehicles is the pre-existing immunity in the human population due to previous exposure from natural infections, particularly adenovirus infections.”
New Insights into the Therapeutic Applications of CRISPR/Cas9 Genome Editing in Breast Cancer
Ahmed, M., Daoud, G. H., Mohamed, A., & Harati, R. (2021) · Genes · doi:10.3390/genes12050723 · Cited by 35
“Its long-lasting transgene expression, mild immune response, impressive infection potency and overall safety profile makes it a favorable approach [153].”
BackgroundRecent Progress and Future Prospective in HBV Cure by CRISPR/Cas
Yang, Y.-C., & Yang, H. (2021) · Viruses · doi:10.3390/v14010004 · Cited by 33
“It is advantageous for its low pathogenicity and immunogenicity, wide range of cell tropism, and long-term expression [71].”
BackgroundDu, C., Cleary, S. P., Kostelic, M. M., Jones, B. J., Kafader, J. O., & Wysocki, V. H. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c02185 · Cited by 31
Immune responses in liver-directed lentiviral gene therapy
Annoni, A., Goudy, K., Akbarpour, M., Naldini, L., & Roncarolo, M. G. (2013) · Translational research · doi:10.1016/j.trsl.2012.12.018 · Cited by 35
Ferla, R., Claudiani, P., Cotugno, G., Saccone, P., Leonibus, E. D., & Auricchio, A. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.213 · Cited by 32
“Gene therapy has the potential to convert a target organ like liver into a factory for the stable systemic production and secretion of therapeutic proteins after a single vector administration (Mingozzi and High, 2011).”
Soni, S. K., Sarkar, S., Mirzadeh, N., Selvakannan, P. R., & Bhargava, S. K. (2015) · Langmuir · doi:10.1021/acs.langmuir.5b00402 · Cited by 30
AL Qtaish, N., Gallego, I., Paredes, A. J., Villate-Beitia, I., Soto-Sánchez, C., Martínez-Navarrete, G., Sainz-Ramos, M., Lopez-Mendez, T. B., Fernández, E., Puras, G., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c02182 · Cited by 29
Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation
Scott, D. W., & Lozier, J. N. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08925.x · Cited by 34
“Clinical trials in patients with haemophilia B have suggested that AAV capsid-specific cytotoxic (CD8) T cell response is responsible for the elimination of AAV-transduced hepatocytes, resulting in therapeutic failure (Mingozzi & High, 2011).”
BackgroundToward a therapy for mitochondrial disease
Viscomi, C. F. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160085 · Cited by 32
Meng, Y., Sun, D., Qin, Y., Dong, X., Luo, G., & Liu, Y. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.019 · Cited by 33
Nucleic acid delivery and nanoparticle design for COVID vaccines
Andresen, J. L., & Fenton, O. S. (2021) · MRS Bulletin · doi:10.1557/s43577-021-00169-2 · Cited by 37
Tyumentseva, M. A., Tyumentsev, A. I., & Акимкин, В. Г. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259812 · Cited by 34
“However, immune responses induced by viral delivery systems can be a crucial factor in limiting the therapeutic potential of the delivered construct for genome editing [13, 14].”
BackgroundAnnual banned‐substance review: analytical approaches in human sports drug testing
Thevis, M., Kuuranne, T., Geyer, H., & Schänzer, W. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1441 · Cited by 33
Non-viral gene therapy for bone tissue engineering
Wegman, F., Öner, F. C., Dhert, W. J. A., & Alblas, J. (2013) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2013.801227 · Cited by 31
“The commonly used viral vectors are retroviruses, adenoviruses, adeno-associated viruses (AAVs) and lenti- and herpes viruses (Lim, 2012; Mingozzi & High, 2012; Sakuma, Barry, & Ikeda, 2012).”
Molecular characterization of the newly identified human parvovirus 4 in the family Parvoviridae
Lou, S., Xu, B., Huang, Q., Zhi, N., Cheng, F., Wong, S. C., Brown, K. E., Delwart, E., Liu, Z., & Qiu, J. (2011) · Virology · doi:10.1016/j.virol.2011.09.033 · Cited by 31
“In contrast, AAVs, members of the genus Dependovirus, are non-pathogenic to humans, and have been widely used as therapeutic vectors in human gene therapy (Brown, 2010; Mingozzi and High, 2011).”
Hong, C. A., Cho, S. K., Edson, J. A., Kim, J., Ingato, D., Pham, B., Chuang, A., Fruman, D. A., & Kwon, Y. J. (2016) · ACS Nano · doi:10.1021/acsnano.6b04155 · Cited by 29
“41,42 Past strategies to overcome this complication, particularly on repeated treatments, often involved the administration of immunosuppres-sants, which resulted in additional signi fi cant clinical risks ( e . g ., opportunistic infections).”
AAV Delivery of Endothelin-1 shRNA Attenuates Cold-Induced Hypertension
Chen, P. G.-F., & Sun, Z. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.047 · Cited by 29
Improving clinical efficacy of adeno associated vectors by rational capsid bioengineering
Sen, D. (2014) · Journal of Biomedical Science · doi:10.1186/s12929-014-0103-1 · Cited by 32
Hwang, J., & Yokota, T. (2019) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2019.5 · Cited by 31
Wang, J., Wang, H., Cui, H., Sun, P., Yang, X., & Chen, Q. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.07.027 · Cited by 28
Therapy Prospects for Mitochondrial DNA Maintenance Disorders
Ramón, J., Vila‐Julià, F., Molina-Granada, D., Molina‐Berenguer, M., Melia, M., García‐Arumí, E., Torres‐Torronteras, J., Cámara, Y., & Martí, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126447 · Cited by 33
Kashiwakura, Y., Ohmori, T., Mimuro, J., Yasumoto, A., Ishiwata, A., Sakata, A., Madoiwa, S., Inoue, M., Hasegawa, M., OZAWA, K., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04851.x · Cited by 29
Supramolecular complexes of DNA with cationic polymers: The effect of polymer concentration
Kondinskaia, D. A., & Gurtovenko, A. A. (2018) · Polymer · doi:10.1016/j.polymer.2018.03.048 · Cited by 28
“been of viral nature [1] and had therefore virus-specific safety issues such as high cytotoxicity and immunogenicity [2].”
Ring finger protein 121 is a potent regulator of adeno-associated viral genome transcription
Madigan, V. J., Yuziuk, J. A., Chiarella, A. M., Tyson, T. O., Meganck, R. M., Elmore, Z. C., Tse, L. V., Hathaway, N. A., & Asokan, A. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007988 · Cited by 28
Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders
Li, M., Lin, Y., Cheng, Q., & Wei, T. (2025) · Cell Proliferation · doi:10.1111/cpr.13808 · Cited by 33
“While AAV vectors have the ability to infect several cell types [137], not all serotypes of AAVs can efficiently target specific tissues or organs.”
Vectorization of Nucleic Acids for Therapeutic Approach: Tutorial Review
Geinguenaud, F., Guénin, E., Lalatonne, Y., & Motte, L. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01053 · Cited by 28
Clinical Evaluations of Toxicity and Efficacy of Nanoparticle-Mediated Gene Therapy
Liang, X., Liu, L., Wei, Y.-Q., Gao, G., & Wei, X. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.069 · Cited by 29
“To date, gene delivery approaches involving viral and nonviral carriers have been intensively studied.(2,3) In general, viral carriers have high efficiency, but can also have issues with immunogenicity and toxicity.”
BackgroundNeurology Care, Diagnostics, and Emerging Therapies of the Patient With Duchenne Muscular Dystrophy
Leigh, F., Ferlini, A., Biggar, D., Bushby, K. M. D., Finkel, R. S., Morgenroth, L. P., & Wagner, K. R. (2018) · PEDIATRICS · doi:10.1542/peds.2018-0333c · Cited by 31
Kumagai, M., Shimoda, S., Wakabayashi, R., Kunisawa, Y., Ishii, T., Osada, K., Itaka, K., Nishiyama, N., Kataoka, K., & Nakano, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.021 · Cited by 29
Lee, G. H., & Kim, S. S. (2016) · Mediators of Inflammation · doi:10.1155/2016/5808215 · Cited by 30
Chai, Z., Sun, J., Rigsbee, K. M., Wang, M., Samulski, R. J., & Li, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.005 · Cited by 27
Wu, Y., Mei, T., Jiang, L., Han, Z., Dong, R., Yang, T., & Xu, F. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.123 · Cited by 30
Hong, S.-A., Seo, J. H., Wi, S., Jung, E. S., Yu, J., Hwang, G., Yu, J. H., Baek, A., Park, S., Bae, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.022 · Cited by 28
Preclinical Evaluation of An Anti-HCV miRNA Cluster for Treatment of HCV Infection
Yang, X. J., Marcucci, K. T., Anguela, X. M., & Couto, L. B. (2013) · Molecular Therapy · doi:10.1038/mt.2012.247 · Cited by 28
Intégration des vecteurs AAV et mutagenèse insertionnelle
Rossi, A., & Salvetti, A. (2016) · médecine/sciences · doi:10.1051/medsci/20163202010 · Cited by 33
Wang, L., Wang, Z., Zhang, F., Zhu, R., Bi, J., Wu, J., Zhang, H., Liu, H., Kong, W., Yu, B., et al. (2016) · International Journal of Medical Sciences · doi:10.7150/ijms.14152 · Cited by 31
“Although recombinant adeno-associated virus vector serotype 2 (rAAV2) has been most widely used in human trials as an early serotype isolated from humans, vectors of other serotypes have been shown to be more effective in gene delivery with lower immunogenicity in humans and different tissue specificities [4-8].”
BackgroundChaanine, A. H., Nonnenmacher, M., Kohlbrenner, E., Jin, D., Kovacic, J. C., Akar, F. G., Hajjar, R. J., & Weber, T. (2014) · Gene Therapy · doi:10.1038/gt.2014.7 · Cited by 25
Chauhan, M., Daugherty, A. L., Khadir, F., Duzenli, O. F., Hoffman, A., Tinklenberg, J. A., Kang, P. B., Aslanidi, G., & Pacak, C. A. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05599-5 · Cited by 27
“The gene therapy field has made significant advancements over the last few decades as there are now Food and Drug Administration (FDA) approved therapies for multiple genetically inherited disorders that were once considered untreatable [1–9].”
BackgroundGene Delivery to Adipose Tissue Using Transcriptionally Targeted rAAV8 Vectors
Uhrig-Schmidt, S., Geiger, M., Luippold, G., Birk, G., Mennerich, D., Neubauer, H., Grimm, D., Wolfrum, C., & Kreuz, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116288 · Cited by 27
“Although AAV is known to induce only mild cellular immune responses [15], we nevertheless checked for tissue inflammation by assessing macrophage infiltration in rAAV-injected vs.”
BackgroundTherapeutic genome engineering via CRISPR ‐Cas systems
Moreno, A. M., & Mali, P. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1380 · Cited by 30
“These have been widely utilized for gene therapy due to their overall safety, mild immune response, long-term transgene expression, high-infection efficiency, and are now already being used in clinical trials.(56) A primary drawback of AAVs, however, is that they have a limited packaging capacity of around 4.”
Adeno‐Associated Viral Vectors for Homology‐Directed Generation of CAR‐T Cells
Moço, P. D., Aharony, N., & Kamen, A. (2019) · Biotechnology Journal · doi:10.1002/biot.201900286 · Cited by 28
Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases
Schreurs, J., Sacchetto, C., Colpaert, R. M. W., Vitiello, L., Rampazzo, A., & Calore, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010985 · Cited by 26
“This vector realizes consistent transgene expression in a broad range of tissues, both mitotic and post-mitotic, including the heart [76].”
BackgroundNeonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice
Pontoizeau, C., Sola, M. S., Gaborit, C., Nguyen, V., Rotaru, I., Tual, N., Colella, P., Girard, M., Biferi, M. G., Arnoux, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30880-w · Cited by 26
Self-citationJackson, M. F., Hoversten, K. E., Powers, J. M., Trobridge, G. D., & Rodgers, B. D. (2013) · FEBS Journal · doi:10.1111/febs.12072 · Cited by 30
Ultramicroscopy as a novel tool to unravel the tropism of AAV gene therapy vectors in the brain
Alves, S., Bode, J., Bemelmans, A., Kalle, C. V., Cartier, N., & Tews, B. (2016) · Scientific Reports · doi:10.1038/srep28272 · Cited by 27
Gene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 26
“One model of this response hypothesizes that the AAV capsid can act as an exogenous antigen that is loaded into the MHC class II molecules on the surface of antigen-presenting cells (APCs), and presented to CD4? T cells [119] (Fig.”
BackgroundBazán, C. (2019) · Journal of Engineering and Technology Management · doi:10.1016/j.jengtecman.2019.05.001 · Cited by 33
Ramzy, A., Tudurí, E., Glavas, M. M., Baker, R. K., Mojibian, M., Fox, J. K., O’Dwyer, S. M., Dai, D. L., Hu, X., Denroche, H. C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67136-w · Cited by 31
Carestia, A., Kim, S.-J., Horling, F., Rottensteiner, H., Lubich, C., Reipert, B. M., Crowe, B. A., & Jenne, C. N. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.023 · Cited by 24
“DISCUSSION Gene therapy offers promise for the treatment of heritable diseases that result from a dysfunctional version of protein.(4) By providing these patients a “working” copy of the defective gene, it is possible to cure some of these diseases, free patients from costly, ongoing therapies, and potentially save li…”
BackgroundInfluentialZhang, T., Song, X., Kang, D., Zhang, L., Zhang, C., Jin, S., Wang, C., Tian, J., Xing, J., & Liang, X. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00548e · Cited by 24
Lotfinia, M., Abdollahpour‐Alitappeh, M., Hatami, B., Zali, M. R., & Karimipoor, M. (2019) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00557-8 · Cited by 28
Wei, Y., Zhao, Z., & Ma, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1037124 · Cited by 29
“Additionally, AAV can have stable transgene expression with long-term existence as a concatemer in nondividing cells (93).”
BackgroundTseng, S. ‐., Kempson, I. M., Peng, S., Ke, B.-H., Chen, H., Chen, P., & Hwu, Y. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.009 · Cited by 24
“Accurate and effective delivery is the key: virus missing their target can manifest morbid side effects including ectopic gene expression or risk eliciting severe immune response [5].”
BackgroundZhang, T., Guo, W., Zhang, C., Yu, J. X., Xu, J., Li, S., Tian, J., Wang, P. C., Xing, J., & Liang, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b03402 · Cited by 24
Rogers, G. L., Chen, H.-Y., Morales, H., & Cannon, P. M. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.019 · Cited by 24
Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase
Cagin, U., Puzzo, F., Gómez, M. J., Moya‐Nilges, M., Sellier, P., Abad, C., van Wittenberghe, L., Danièle, N., Guerchet, N., Gjata, B., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.025 · Cited by 27
Self-citationZhou, Q., Tian, W., Liu, C., Lian, Z., Dong, X., & Wu, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-04054-4 · Cited by 23
Genome Editing in Neurosciences
Jaenisch, R., Gage, F. H., & Zhang, F. (2017) · Research and perspectives in neurosciences · doi:10.1007/978-3-319-60192-2 · Cited by 24
So, W. Y., Liu, W. N., Teo, A. K. K., Rutter, G. A., & Han, W. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb1038 · Cited by 24
Lin, Y., Li, C., Wang, W., Li, J., Huang, C., Zheng, X., Liu, Z., Song, X., Chen, Y., Gao, J., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1115348 · Cited by 23
“Although AAV has become one of the key tools for preclinical and clinical gene therapy research, how to deliver these AAV carrying the transgenes to the affected brain regions remains a challenge (Mingozzi and High, 2011).”
BackgroundChemical approaches to probe and engineer AAV vectors
Pham, Q. T., Glicksman, J., & Chatterjee, A. (2024) · Nanoscale · doi:10.1039/d4nr01300j · Cited by 26
Enhanced T Cell Function in a Mouse Model of Human Glycosylation
Buchlis, G., Odorizzi, P. M., Soto, P. C., Pearce, O. M. T., Hui, D. J., Jordan, M. S., Varki, A. P., Wherry, E. J., & High, K. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202905 · Cited by 24
“The generally accepted hypothesis accounting for immune responses generated against the AAV vector in humans is that a preexisting memory pool of T cells from an early childhood infection is reactivated upon gene transfer and attacks virally infected cells (44).”
BackgroundSelf-citationAdriouch, S., Franck, E., Drouot, L., Bonneau, C., Jolinon, N., Salvetti, A., & Boyer, O. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00199 · Cited by 22
“Therefore, developing strategies to circumvent immune responses and facilitate long-term expression of transgenic therapeutic proteins has been identified as one of today’s main challenges for the translation of rAAV vectors into the clinic (Mingozzi and High, 2011a,b; Nayak and Herzog, 2011).”
BackgroundA magic bullet to specifically eliminate mutated mitochondrial genomes from patients' cells
Moraes, C. T. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303769 · Cited by 24
“Viral vectors, such as AAV (Mingozzi and High, 2011), are one of the tools of choice, and although they have limitations on the size of the DNA that can be packaged, mtZFN may be a bit smaller and more amenable to packaging in a single virion when compared to mitoTALEN.”
Adeno-Associated Viral Vectors at the Frontier between Tolerance and Immunity
Mingozzi, F., & Büning, H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00120 · Cited by 31
Self-citationGil-Fariña, I., Scala, M. D., Vanrell, L., Olagüe, C., Vales, Á., High, K. A., Prìeto, J., Mingozzi, F., & González‐Aseguinolaza, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067748 · Cited by 26
“[1].”
Self-citationHuang, W., McMurphy, T. B., Liu, X., Wang, C., & Cao, L. (2016) · Molecular Therapy · doi:10.1038/mt.2016.34 · Cited by 24
Kavita, U., Dai, Y., Salvador, L., Miller, W., Adam, L. P., Levesque, P. C., Zhang, Y. J., Ji, Q. C., & Pillutla, R. C. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.131 · Cited by 23
“Our results suggest a strong correlation between the total and neutralizing Ab assays for AAV serotype 9 in this patient population.”
Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy
Liu, Y., Siriwon, N., Rohrs, J. A., & Wang, P. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150531171653 · Cited by 26
“AAV2 vectors have been used in an increasing number of clinical trials, including cystic fibrosis [21], retinal degenerative disorders [22-24] and hemophilia B [25, 26].”
BackgroundPiacentino, V., Milano, C. A., Bolanos, M. D., Schroder, J. N., Messina, E., Cockrell, A. S., Jones, E., Krol, A., Bursac, N., Mao, L., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.186 · Cited by 26
“AAVderived vectors are increasingly receiving U.S. Food and Drug Administration (FDA) approval for therapeutic gene delivery in a number of clinical trials (Mingozzi and High, 2011).”
BackgroundCramer, M. L., Shao, G., Rodino-Klapac, L. R., Chicoine, L. G., & Martin, P. T. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.113 · Cited by 22
“T-cell clones specific to peptides within the AAV capsid protein or to peptides from the protein produced by the delivered transgene can weaken the expression of the therapeutic transgene over time.(1) High et al.”
BackgroundSavarala, S., Brailoiu, E., Wunder, S. L., & Ilies, M. A. (2013) · Biomacromolecules · doi:10.1021/bm400591d · Cited by 23
Wang, X., Skelley, L. A., Wang, B., Mejia, A., Sapozhnikov, V., & Sun, Z. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.078 · Cited by 22
“…have shown that AAV is a safe vector for animal studies (Wang et al., 2006; Wang and Sun, 2009; Crosswhite and Sun, 2010; Flotte et al., 2011; Mingozzi and High, 2011). shRNAs delivered by AAV-2 have been used for regulating gene expression in cultured cells (Tenenbaum et al., 2004; Michel…”
BackgroundInfluentialHösel, M., Lucifora, J., Michler, T., Holz, G., Gruffaz, M., Stahnke, S., Zoulim, F., Durantel, D., Heikenwälder, M. F., Nierhoff, D., et al. (2014) · Hepatology · doi:10.1002/hep.26990 · Cited by 25
“V ectors based on the adeno-associated virus (AAV), a nonpathogenic member of the parvoviridae, have become increasingly popular as a gene transfer vehicle, in particular, for in vivo gene therapy.(1) They deliver a DNA genome within a tightly packaged nonenveloped protein capsid that mediates cell transduction.”
BackgroundMethodHuman Retinal Explant Culture for Ex Vivo Validation of AAV Gene Therapy
Orlans, H. O., Edwards, T. L., Silva, S. R. D., Patrício, M. I., & MacLaren, R. E. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_21 · Cited by 24
Constructing efficient polycationic gene carriers through regulating the physicochemical properties
Fang, H., Feng, Y., Chen, J., Tian, H., & Chen, X. (2018) · Materials Today Chemistry · doi:10.1016/j.mtchem.2018.11.007 · Cited by 22
Lee, S., & Ahn, H. J. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.04.044 · Cited by 23
Khan, K., Makhoul, G., Yu, B., Schwertani, A. G., & Cecere, R. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370219851243 · Cited by 23
Sheddable, degradable, cationic micelles enabling drug and gene delivery
Li, Y., Lei, X. Q., Dong, H., & Ren, T. (2014) · RSC Advances · doi:10.1039/c3ra46756b · Cited by 23
Studies of Efficacy and Liver Toxicity Related to Adeno-Associated Virus–Mediated RNA Interference
Sun, C., Wu, T., Chen, C., Wu, P., Shih, Y., Tsuneyama, K., & Tao, M. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.239 · Cited by 26
“Adeno-associated virus (AAV)–based vectors represent a promising delivery system for RNAi-based therapy because of their ability to infect both dividing and nondividing cells, to achieve extensive target organ transduction in vivo, and to direct long-term gene expression in these tissues (Mingozzi and High, 2011; Van…”
BackgroundWu, C., Liu, F., Li, P., Zhao, G., Lan, S., Jiang, W., Meng, X., Tian, L., Li, G., Li, Y., et al. (2014) · Cell Transplantation · doi:10.3727/096368914x681919 · Cited by 22
“tary or metabolic disorders (28), and its success relies largely on an effective and targeted gene delivery system”
BackgroundSellier, P., Vidal, P., Bertin, B., Gicquel, E., Bertil-Froidevaux, E., Georger, C., van Wittenberghe, L., Miranda, A., Danièle, N., Richard, I., et al. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12625 · Cited by 25
“60 If this growth-dependent vector dilution in muscle is confirmed and given the formation of high titer anti-AAV antibodies after the injection of AAV vectors, strategies may be needed to be able to cope with vector re-administration.”
BackgroundSelf-citationDetection of EPO gene doping in blood
Neuberger, E. W. I., Jurkiewicz, M., Moser, D., & Simon, P. D. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1347 · Cited by 23
Adeno‐Associated Virus Vector–Based Gene Therapy for Monogenetic Metabolic Diseases of the Liver
Junge, N., Mingozzi, F., Ott, M., & Baumann, U. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000703 · Cited by 23
“For details, see Mingozzi and High (23).”
BackgroundSelf-citationHan, L., Wang, W., Lu, J., Kong, F., Ma, G., Zhu, Y., Zhao, D., Zhu, J., Shuai, W., Zhou, Q., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.006 · Cited by 22
“Recombinant AAV has been used widely as a gene delivery vehicle in a wide range of cells in vitro and in vivo [29–32].”
MethodCreation of a cardiotropic adeno-associated virus: the story of viral directed evolution
Yang, L., & Xiao, X. (2013) · Virology Journal · doi:10.1186/1743-422x-10-50 · Cited by 24
Bardakjian, T., & Gonzalez‐Alegre, P. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63233-3.00008-7 · Cited by 24
Killian, T., Buntz, A., Herlet, T., Seul, H., Mundigl, O., Längst, G., & Brinkmann, U. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz137 · Cited by 21
The gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.375.3797885 · Cited by 23
Self-citationSelot, R., Arumugam, S., Mary, B., Cheemadan, S., & Jayandharan, G. R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00441 · Cited by 20
“Gene therapy using recombinant Adeno-associated virus (Serotypes AAV1 to AAV12) has gained significant attention after early success with several pre-clinical and clinical studies (De et al., 2006; Zincarelli et al., 2008; Mendell et al., 2010; Mingozzi and High, 2011; Nathwani et al., 2011).”
BackgroundMicroRNA‐384 Inhibits the Progression of Papillary Thyroid Cancer by Targeting PRKACB
Wang, Y., Wang, B., Zhou, H. W., Zhang, X., Qian, X., & Cui, J. (2020) · BioMed Research International · doi:10.1155/2020/4983420 · Cited by 22
RNA‐based therapeutic approaches for coagulation factor deficiencies
Pinotti, M., Bernardi, F., Mas, A. D., & PAGANI, F. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04481.x · Cited by 25
Gene Therapy: A Promising Approach to Treating Spinal Muscular Atrophy
Mulcahy, P. J., Iremonger, K., Karyka, E., Herranz-Martín, S., Shum, K., Tam, J. K. V., & Azzouz, M. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.186 · Cited by 21
“Ex vivo gene transfer refers to a strategy in which the target cells are removed from the individual to be treated, genetically modified in the laboratory, and then re-administered to the patient (Dominguez et al., 2011; Mingozzi and High, 2011).”
InfluentialCotugno, G., Annunziata, P., Barone, M. V., Karali, M., Banfi, S., & Auricchio, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033286 · Cited by 22
“Systemic administration of AAV2/8 results in long-term, robust transgene expression with minimal toxicity and immune responses in several animal models [4,5].”
BackgroundMethodInfluentialGilkes, J. A., Bloom, M. D., & Heldermon, C. D. (2015) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2015.11.006 · Cited by 22
“…r t i c l e i n f o Article history: Received 9 November 2015 Received in revised form 30 November 2015 Accepted 30 November 2015 Available online 7 December 2015 Sanfilippo syndrome type B (MPS IIIB) is a lysosomal storage disease caused by a deficiency of N-acetylglucosaminidase (NAGLU) activity.”
BackgroundHardet, R., Chevalier, B., Dupaty, L., Naïmi, Y., Riou, G., Drouot, L., Jean, L., Salvetti, A., Boyer, O., & Adriouch, S. (2016) · Molecular Therapy · doi:10.1038/mt.2015.146 · Cited by 19
Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Lukschal, A., Stremnitzer, C., Roth‐Walter, F., Weghofer, M., Ritter, M., Tossi, K. P., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1171446 · Cited by 20
Aledort, L. M. (2016) · Haemophilia · doi:10.1111/hae.12970 · Cited by 20
Stone, D., Kenkel, E. J., Loprieno, M. A., Tanaka, M., Feelixge, H. S. D. S., Kumar, A. J., Stensland, L., Obenza, W., Wangari, S., Ahrens, C. Y., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.113 · Cited by 21
Metadata
- Authors
- Mingozzi, F., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- High, Katherine A.
- Venue
- Nature Reviews Genetics
- Published
- 2011-04-18
- Volume
- 12
- Issue
- 5
- Pages
- 341-355
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2012894204
- Cited by
- 893
- References
- 177
- Citations by year
- 2026: 13 · 2025: 30 · 2024: 51 · 2023: 39 · 2022: 43 · 2021: 53 · 2020: 66 · 2019: 62 · 2018: 66 · 2017: 80 · 2016: 70 · 2015: 82 · 2014: 74 · 2013: 73 · 2012: 65
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-05-24)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Heart, Lung, and Blood Institute (P01HL064190, HL64190, HL078810, P01HL078810)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- adeno-associated virus vectors, gene therapy, in vivo gene delivery, genetic disorders, gene replacement, inherited retinal disease, hemophilia B
- MeSH terms
- Dependovirus, Animals, Hemophilia B, Clinical Trials as Topic, Dogs, Genetic Vectors, Humans, Male, Retinal Diseases, Genetic Therapy, Gene Transfer Techniques, Genetic Diseases, Inborn, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.